First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Aug. 15, 2023 (HealthDay News) — For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according to a study published online Aug. 5 in The Lancet<\/em>.<\/p>\n Siow Ming Lee, M.B.B.S., Ph.D., from the University College London, and colleagues conducted a randomized controlled trial at 91 sites in 23 countries to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy among patients with stage IIIB or IV NSCLC in whom platinum-doublet chemotherapy was deemed unsuitable. A total of 453 patients were enrolled and randomly assigned to atezolizumab or chemotherapy (302 and 151 patients, respectively).<\/p>\n The researchers found that compared with chemotherapy, atezolizumab improved overall survival (median overall survival, 10.3 versus 9.2 months; stratified hazard ratio, 0.78), with a two-year survival rate of 24 percent with atezolizumab and 12 percent with chemotherapy. Atezolizumab was associated with stabilization or improvement of patient-reported health-related quality-of-life functioning scales and symptoms compared with chemotherapy, and with fewer grade 3 to 4 treatment-related adverse events (16 versus 33 percent) and treatment-related deaths (1 versus 3 percent).<\/p>\n “First-line atezolizumab was associated with improved survival and a doubling of the two-year survival rate, despite over 50 percent of patients in the chemotherapy arm who were still alive at two years receiving subsequent immunotherapy,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including F. Hoffmann-La Roche and Genentech, who funded the study; Genentech is the manufacturer of atezolizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n